SPI Pharma Launches ValensTM to Unify Vaccine and Biologic Offerings
SPI Pharma's ValensTM unites products for vaccines, biologics, and parenteral dosage forms.
Breaking News
Jul 25, 2024
Mrudula Kulkarni
ValensTM is a new portfolio brand name from SPI Pharma that
unites product offerings aimed at serving the vaccine, parenteral dosage form,
and biologic medicine markets.
In order to support the rapidly expanding biologics drug
excipients market, SPI Pharma's unique vaccine adjuvant products will first be
grouped under the ValensTM brand. This brand will also be used to strategically
brand new additions to the portfolio, with the goal of creating a comprehensive
offering of parenteral excipients, vaccine ingredients, and materials.
For many years, SPI dominated the market for alum vaccine
adjuvants. Now, to expand its offering, it has partnered with Q-Vant
Biosciences to bring in sustainable saponin adjuvants. Additionally, SPI
recently decided to work strategically with Inimmune Corp. to create and market
cutting-edge adjuvant solutions. The business development team at SPI is
currently exploring several materials and pursuing potential partnerships to
further enhance the portfolio.
Valens will set the high-value parenteral, biologic, and
vaccine ingredients apart from the other pharmaceutical and consumer health
products offered by SPI Pharma.
"The Latin term Valens means "strong, energetic,
and healthy," and these qualities aptly characterise our ValensTM range of
adjuvants and parenteral medicines. Our ValensTM portfolio, developed to
improve life-saving vaccinations and medicines, embodies SPI Pharma's
fundamental philosophy of making a difference. "We want to make these
cutting-edge and complementary products available to everyone on the
planet," stated John McInerney.